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and Robert A Yood3
Abstract
Background: For patients to effectively manage gout, they need to be aware of the impact of diet, alcohol use,
and medications on their condition. We sought to examine patients’ knowledge and beliefs concerning gout and
its treatment in order to identify barriers to optimal patient self-management.
Methods: We identified patients (≥18 years of age) cared for in the setting of a multispecialty group practice
with documentation of at least one health care encounter associated with a gout diagnosis during the period
2008–2009 (n = 1346). Patients were sent a questionnaire assessing knowledge with regard to gout, beliefs about
prescription medications used to treat gout, and trust in the physician. Administrative electronic health records
were used to identify prescription drug use and health care utilization.
Results: Two hundred and forty patients returned surveys out of the 500 contacted for participation. Most were
male (80%), white (94%), and aged 65 and older (66%). Only 14 (6%) patients were treated by a rheumatologist.
Only a minority of patients were aware of common foods known to trigger gout (e.g., seafood [23%], beef [22%],
pork [7%], and beer [43%]). Of those receiving a urate-lowering medication, only 12% were aware of the short-term
risks of worsening gout with initiation. These deficits were more common in those with active as compared to
inactive gout.
Conclusion: Knowledge deficits about dietary triggers and chronic medications were common, but worse in those
with active gout. More attention is needed on patient education on gout and self-management training.
Keywords: Beliefs, Treatment, Gout, Dietary influence, Physician-patient communication
Background
Gout is a common cause of inflammatory arthritis affect-
ing up to 6 million Americans [1]. The prevalence of
gout increases with advancing age and is associated with
diuretic use, low dose aspirin, hypertension, cardiovascu-
lar disease, chronic renal insufficiency, and metabolic
syndrome [2]. Both diet and alcohol intake have been
shown to be risk factors for incident gout as well as trig-
gers for recurrent attacks in those with the condition
[3-5]. Specifically, higher levels of meat (beef and pork)
and seafood consumption as well as beer and spirits (but
not moderate amounts of wine) in gout patients are
associated with gout flares [6,7]. Acute gouty symptoms
are usually treated with nonsteroidal anti-inflammatory
drugs (NSAIDs), colchicine, or glucocorticosteroids,
while chronic gout is managed using urate-lowering
therapy such as allopurinol, febuxostat, probenecid and
sulfinpyrazone [8].
Self-management of gout by patients is complex due
to the impact of diet and alcohol on symptoms as well
as the different classes of medications used based on
whether treatment is directed towards acute versus
chronic symptoms [9]. Our preliminary work and that of
others suggests that patients typically receive very little
education on the dietary and lifestyle factors associated
with gout [9,10]. These deficits in patient education may
contribute to medication nonadherence. In particular,
patients may be unaware of the risks of gout flares with
initiation of urate-lowering medications [9]. Thus when
flares occur, patients may assume the medication is not
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working and therefore stop taking it [9,11]. Additionally,
they may be unaware or believe that medications are not
to be used chronically since multiple studies have shown
that the majority of patients do not use urate-lowering
medications regularly [12-17]. In fact, a recent study
comparing medication nonadherence across 7 common
chronic conditions such as hypertension, osteoporosis,
and diabetes mellitus found adherence was lowest with
gout [18].
The purpose of this study was to identify patient
knowledge and beliefs regarding gout and its manage-
ment. We hypothesized that substantial numbers of
patients are unaware of the impact of diet and alcohol
intake on gout flares as well as the risks and benefits of
chronic gout medications. A better understanding of
these issues is critical in order to identify barriers to op-
timal patient self-management.
Methods
We identified eligible patients based on enrollment in
the Fallon Community Health Plan (FCHP) (a managed
care plan) in Central and Eastern Massachusetts, United
States. The patient study population included only mem-
bers of the group-model component of the plan who
received care from Reliant Medical Group (formerly
Fallon Clinic), a multispecialty group practice. The com-
puterized information system of the health plan contains
records on utilization of all health care services includ-
ing encounters and diagnostic testing as well as medical
diagnoses and prescription drug dispensings. A total of
191,000 individuals were enrolled in the health plan in
2009. We identified members from the dataset who met
criteria for enrollment into the cohort: age at least
18 years with at least one diagnosis code for gout (ICD-
9 code 274.XX) in the prior 2 years (2008–2009) and
were enrolled at least 12 months prior to the survey ad-
ministration. There were 500 members contacted for
participation in the study in the first 2 weeks of January
2010. The study was approved by institutional review
boards at FCHP, Reliant Medical Group and the Univer-
sity of Massachusetts Medical School and patients pro-
vided consent prior to enrollment into the study.
Health care utilization and status
Administrative health records were used to identify pre-
scription drug dispensings, health care utilization, and
inpatient and outpatient diagnosis in the 1 year prior to
the survey administration. Diagnoses for gout and
comorbidities were captured based on International
Classification of Diseases 9th Revision (ICD-9) codes
used by physicians for administrative purposes. All
patients in this study had prescription drug coverage
through the managed care plan. Initiation of a urate-
lowering drug was identified based on a dispensing of
allopurinol and probenecid (no patients received sulfin-
pyrazone or febuxostat during the study period). Patients
were asked to report using their gout-related health care
encounters (ambulatory and emergency department) and
procedures (injections and radiographic studies) in the
questionnaire. Since self-reported health care utilization
was similar to the administrative claims, we present here
self-reported utilization (data not shown).
Questionnaire content
The questionnaire was developed to include questions
on the following topics: knowledge regarding gout (in-
cluding etiology, dietary triggers, and the role of urate-
lowering medications); beliefs about prescription medi-
cations used to treat gout (including ease of administra-
tion, effectiveness in decreasing pain, and associated side
effects); overall health motivation; and trust in the phys-
ician. The items assessing overall health motivation and
trust were drawn from existing measures [19-21]. The
knowledge and belief items were developed by the
authors for this present study. A number of background
items were included (e.g., age, education, self-rated
health). Preliminary versions of the questionnaire were
pre-tested using cognitive interviews with a convenience
sample of 5 patients in 1:1 sessions. A brief description
of each set of items follows.
Gout-related knowledge–etiology and general principles of
treatment
The questions we developed to test knowledge of the eti-
ology of gout were based on our previous in-depth inter-
views with patients in which we identified common
deficits that impacted optimal self-management [9]. Two
of the authors drafted the items (LRH, a rheumatologist
and KMM, a psychometrician with experience in item
writing). The draft items were reviewed and revised by
all authors. Cognitive interviews were conducted using
the draft items; the items were again reviewed and
revised by the authors based on these results. The final
set of questions included four items for patients to re-
spond to with options of “True,” “False” and “Not Sure.”
The statements were focused on the etiology of gout
(e.g., “Gout is caused by too much uric acid,” “Gout
flares can result from crystals forming in and around
joints”), the need for chronic therapy as opposed to
intermittent medication use in those started on urate-
lowering therapy (e.g., “Medications which lower uric
acid such as allopurinol or probenecid can be taken only
when you have a gout flare”), and awareness of risks of
flare triggered by medications (e.g., “Chronic gout medi-
cations such as allopurinol or probenecid can cause gout
flares when the medications are started”). Each item was
scored with 1 point given for each correct answer and 0
for incorrect or “Not Sure” responses.
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Gout related knowledge-diet and alcohol consumption
A 10-item test of dietary and alcohol products that can
trigger gout was developed for this study as there were
no previously developed instruments available in the
published literature. The diet/alcohol test was developed
based on available published literature that found an as-
sociation between the consumption of these products
and acute gouty symptoms and the current gout treat-
ment recommendations which suggest providers should
counsel patients on this topic [6,7,22,23]. Three response
options included: “Yes, might cause a flare,” “No prob-
ably would not cause a flare,” and “Not sure.” Each item
was scored with 1 point given for each correct answer
and 0 for incorrect or “not sure” responses. A summary
dietary knowledge score was created based on a total
score (range 0–10 with the higher score reflecting
greater knowledge).
Beliefs about gout and medications
A total of 31 items were developed to assess beliefs
about gout severity, gout medication efficacy, negative
perceptions of prescription medications, and barriers to
medication use. These items were developed based on
the work by members of the research team (RAY and
KMM) previously in osteoporosis and based on the
health belief model [24,25]. These questions were revised
to make them specific to gout by one author (LRH) and
reviewed and edited by all authors. Draft items were
tested in cognitive interviews, and all authors reviewed
and revised the items before inclusion in the final ques-
tionnaire. Response options for all belief items were
“Strongly Agree,” “Agree,” “Neutral,” “Disagree” and
“Strongly Disagree.” The items were grouped into 3
scales: 1) beliefs in acute medications (6 questions each
for nonsteroidal anti-inflammatory drugs, colchicine and
glucocorticoids), 2) beliefs regarding the need for and ef-
fectiveness of chronic gout therapy as well as barriers to
use of these chronic agents (9 questions), and 3) beliefs
regarding prescription medications in general (3
questions).
Health motivation
Lastly 4 questions were included on health motivation and
adapted from the Osteoporosis Health Belief Scale [21,25].
These questions are not condition specific but rather as-
sess overall motivation with regards to health. A sample
question was “Keeping healthy is very important to me.”
Response options were “Strongly Agree,” “Agree,” “Neu-
tral,” “Disagree” and “Strongly Disagree” with higher
scores suggesting greater health motivation. For this score,
we combined the “Strongly agree” and “Agree” responses.
Each item was scored with 1 point given for agreement to
a statement suggesting strong health motivation and
a 0 for “Neutral,” “Disagree,” and “Strongly Disagree”
responses. The resulting range was 0–4 with the higher
score reflecting greater health motivation.
Trust in the physician treating the gout
The short form of the trust scale was developed by
Dugan and colleagues and consists of five questions [19].
An example from this set was “All in all, I have complete
trust in my doctors.” Five response options were pro-
vided and were as follows: “Strongly disagree,” “Dis-
agree,” “Uncertain,” “Agree” and “Strongly agree.”
Responses were scored so that a higher score indicated
higher trust. For example, for positive statements such
as “I completely trust my doctor’s decisions about which
medical treatments are best for me,” we assigned a score
of 1 for a response of “Strongly agree” or “Agree” and a
0 for “Uncertain,” “Disagree,” and “Strongly Disagree.”
For negative statements such “Sometimes my doctor
cares more about what is convenient for him/her than
my medical need,” we assigned a score of 1 for a re-
sponse of “Strongly disagree” or “Disagree” and a 0 for
“Uncertain,” “Agree,” and “Strongly Agree.” A summary
trust in the physician score was created through taking
the mean score across the five items (range 0–5).
Questionnaire administration
A random sample of 500 patients who met eligibility cri-
teria were sent a letter informing them about the study.
Patients were notified that they could opt out of the
study by contacting a toll-free number. One week after
the letter, those patients who did not decline to partici-
pate were sent a self-administered questionnaire with $5
cash and a research authorization and consent form per-
mitting review of electronic medical records. Two
reminders were sent to those not returning the question-
naire (each 10 to 14 days after the prior mailing).
Analyses
Statistical analyses
Overall there was a low rate of missing data (<4%) for
the specific instruments. We excluded missing values
from the analyses. Cronbach’s alpha was computed to
assess score reliability for gout knowledge on dietary
triggers, general beliefs about prescription medications,
health motivation, and trust in physician. Initial analyses
were performed using descriptive statistics. For continu-
ous variables we calculated means and standard devia-
tions. For mean scores we calculated 95% confidence
intervals. For categorical variable, proportions were cal-
culated. We used Chi square or Fisher’s exact test for
discrete variables and t-test or the Wilcoxon test for
continuous variables. Specifically we identified patients
with “active gout” which we defined as those patients
reporting 2 or more gout flares that required medical
care (an outpatient or Emergency Department visit) in
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the past 6 months and compared them to those without
active gout. As sensitivity analyses, we also examined
whether there were differences based on gout utilization
(comparing those with ≥ 1 encounter of gout in the prior
12 months vs. those with none) and disease stage com-
paring those with receipt of a urate-lowering drug (used
as a proxy for chronic gout) to those not on those
agents.
Results
Of the 500 eligible patients contacted for participation
in the study including filling out the questionnaire and
providing access to their claims data, 121 declined par-
ticipation and 139 did not respond. This resulted in 240
patients who responded (response rate of 51% after ex-
cluding patients who reported never having gout n = 33;
gout was likely a “rule out” diagnosis by providers, and
upon review of additional evidence the patients were
considered to not have gout). There were no significant
differences between responders and nonresponders in
terms of age, gender, and number of claims for gout.
However, nonresponders were less likely to be dispensed
a urate lowering drug (36% vs. 46%, p = 0.03). The base-
line characteristics of the overall patient population are
shown in Table 1. The majority of patients were male
(80%), white (94%), and aged 65 and older (67%). Alco-
hol use, defined as having 2 or more drinks in the past
7 days, was reported by 45%. Comorbid conditions such
as dyslipidemia (83%), hypertension (78%), diabetes
(39%), and coronary heart disease (32%) were common.
Based on pharmacy dispensings in the prior 12 months,
47% received a urate-lowering drug, 36% an NSAID,
26% colchicine, and 19% a glucocorticoid. Only 14
patients (6%) were cared for by a rheumatologist, and
they were not more knowledgeable about dietary trig-
gers; however, they were more likely to be aware of the
risk of acute gouty symptoms with initiation of urate-
lowering therapy (p =0.04).
There were 53 patients (22%) who reported active gout
(required ≥2 ambulatory or Emergency Department vis-
its for active gout). They were more likely to be female
(30% vs. 17%; p = 0.028), aged 75 and older (45% vs. 22%;
p = 0.016) and less likely to report alcohol use (25% vs.
43%; p = 0.014) than those without active gout. They
were also more likely to have received a prescription in
the prior 12 months for a urate-lowering drug (70% vs.
41%; p = 0.0002), colchicine (43% vs. 21%; p = 0.002), and
a glucocorticoid (36% vs. 14%; p = 0.001). While they
were more likely to be cared for by a rheumatologist
(18% vs. 4%; p =0.001), >80% were cared for solely by a
primary care provider. In terms of gout-related self-
reported health care utilization in the prior 6 months
(Table 2), overall 44% reported ≥1 ambulatory encoun-
ters, 5% ≥1 emergency department visits, and 5% ≥1
joint injections with more utilization occurring in those
with active gout. Additionally, those with active gout
were more likely to report missing work in the last
6 months due to gout than those without active gout
(13% vs. 4%; p = 0.001).
The vast majority of patients knew that gout was
related to uric acid (89%) and flares were the result of
crystals inducing inflammation in and around joints
(80%); however only 25% of patients who received a
urate-lowering medication in the past year were aware
that these medications were to be used chronically and
only 12% knew that initiation of urate-lowering drugs
could worsen gout in the short term. Many participants
were unaware of foods that may lead to a gout flare
(mean score of 3.4 [±2.3]; range 0–10; alpha = 0.68)
(Table 3). Specifically, more patients incorrectly reported
vegetables (58%), chicken (55%) and legumes (39%) as
triggers as compared to foods documented to cause gout
flares including seafood (23%), beef (22%) and pork (7%).
Only 43% knew that beer intake could increase the
chances of a gout flare. Awareness of dietary triggers
was worse in those with active gout (means score of 2.7
vs. 3.6; p value = 0.014).
For the management of acute flares, nonsteroidal anti-
inflammatory drugs were considered by patients to be
easy to take (86%) and effective in decreasing pain (78%)
with only 23% having side effects to the agents. Among
colchicine users, colchicine was considered easy to take
(91%) and effective (76%) but 37% reported side effects
to the medication. The responses did not differ based on
disease activity. Views on the need for chronic gout ther-
apy as well as barriers to the use of these agents were
similar in those with and without active gout. However,
those with active gout were less likely to report that
chronic gout medications prevent gout flares (56.3% vs.
77.8%, p = 0.026). Both groups had similar responses
when asked about beliefs in prescription medications
overall including distrust or concerns (12.2 and 11.9
with a range of 1–20; alpha = 0.79). The majority of
patients reported high levels of trust in their physician
(mean score of 21.5 [±4.1]; range 5–25; alpha = 0.89) and
high levels of health motivation (mean score of 23.0
[±4.1]; range 6–30; alpha = 0.80). The responses were
not different based on gout activity.
Discussion
Our study provides new information on patient know-
ledge and beliefs regarding gout management. Several
deficits in knowledge were identified in the total popula-
tion including dietary triggers, dosing of urate-lowering
medications during flares, and the risk of this drug class
in causing worsening gout in the short-term. However,
the deficits were greater in those with active gout. In
contrast, mean scores for health motivation, beliefs
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Table 1 Characteristics of the gout patients who responded to the questionnaire
Demographics Total
N= 240
Active gout
N=53
Inactive gout
N=187
P value
Age (N and%) 0.016
<65 81 (34) 12 (23) 69 (37)
65-74 93 (39) 17 (32) 76 (41)
75 or older 66 (28) 24 (45) 42 (22)
Gender (% male) 193 (80) 37 (70) 156 (83) 0.028
Race (N and%) 0.825
Caucasian 225 (94) 50 (94) 175 (94)
Native American 9 (4) 2 (4) 7 (4)
Hispanic 3 (1) 1 (2) 2 (1)
Black 2 (1) 0 (0) 2 (1)
Asian 1 (0) 0 (0) 1 (1)
Highest grade completed (N and%) 0.331
No high school degree 33 (14) 9 (18) 24 (13)
High school graduate 86 (36) 19 (37) 67 (36)
College 118 (50) 23 (45) 95 (51)
Health Behaviors
Current smoking (N and%) 13 (5) 3 (6) 10 (5) 0.929
Alcohol use* (N and%) 94 (39) 13 (25) 81 (43) 0.014
Associated Conditions
Dyslipidemia (N and%) 196 (82) 45 (85) 151 (82) 0.581
Hypertension (N and%) 185 (78) 44 (83) 141 (76) 0.295
Diabetes mellitus (N and%) 91 (38) 22 (42) 69 (37) 0.579
Coronary heart disease (N and%) 77 (32) 21 (40) 56 (30) 0.200
Renal disease (N and%) 43 (18) 12 (23) 31 (17) 0.327
Peripheral arterial disease (N and%) 21 (9) 8 (15) 13 (7) 0.069
Nephrolithiasis (N and%) 17 (7) 4 (8) 13 (7) 0.897
Gout history
Gout encounters (mean, ± SD)** 1 (2) 2 (3) 1 (2)
Cared for by a rheumatologist (N and%) 14 (6) 8 (19) 6 (4)
ULD dispensing (N and%) ** 108 (47) 37 (70) 77 (42) 0.0004
Colchicine use (N and%)** 59 (26) 23 (43) 37 (21) 0.0011
Glucocorticoid use (N and%)** 44 (19) 19 (36) 26 (14) 0.0005
NSAID use (N and%)** 72 (32) 14 (26) 60 (33) 0.355
* reports having 2 or more drinks of alcohol in the last 7 days.
** based on visits or dispensing of urate-lowering drugs (ULDs), colchicine, steroids and NSAIDs in the prior 12 months.
Table 2 Proportion of patients reporting health care utilization for gout over the prior months 6 months
Type of Care Total population Stratified by disease activity
N (%) Active gout
N (%)
Not active gout
N (%)
P value
Ambulatory encounter 84 (35) 51 (96) 33 (18) 0.0001
Emergency Department encounter 12 (5) 12 (23) 0 (0) 0.0001
Joint injection 11 (5) 7 (13) 4 (2) 0.0008
Radiology study 33 (14) 20 (38) 13 (7) 0.0001
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regarding the utility of prescription medications, and
trust in the treating provider were high in all gout
patients. The patients with acute gout were a unique
subset with a greater predominance of women, lower
reported use of alcohol and greater likelihood of being
cared for by a rheumatologist. Limited conclusions can
be made since we know very little in terms of burden of
disease, prior treatments and duration of gout therapy as
well as potential limitations to the use of urate-lowering
therapy in this subpopulation. However, further investi-
gation is needed into this subgroup so that health care
providers can target them for intensive treatment in
order to control gout.
A few epidemiologic studies have examined the rela-
tionship between dietary factors and uric acid levels and
gout flares [4,6,7,26]. Specifically, there is an increased
risk of gout with higher levels of beef, pork and seafood
consumption [6]. Moderate consumption of purine-rich
vegetables have not been associated with an increased
risk of gout. However, over half the patients in our study
believed that intake of vegetables was associated with a
risk of flare while only about one quarter were aware of
the true association with beef or seafood. Similarly, beer
is well known to trigger recurrent gout attacks, often oc-
curring within 24 hours after alcohol consumption [7].
However, in our study fewer than half of the patients
reported beer as a potential cause of gout flares.
In this study, lack of awareness regarding the need for
chronic therapy with urate-lowering medications as well
as short-term risk of acute gout symptoms with initi-
ation of this class of medications may help explain the
results of larger epidemiologic studies, specifically that
most patients who initiate a urate-lowering medication
have large gaps in drug use over the first year [14-17]
with most returning to treatment over the next 4 years
[27]. While interruptions in medication drug use com-
monly occur due to financial concerns or side effects, it
is less likely these factors played a role given the avail-
ability of generic medications with modest copayments
and that most patients eventually restarted their prior
urate-lowering medication.
Several factors may contribute to the patient knowledge
deficits and incorrect medication beliefs identified here. In
part, our findings may reflect how medical care is deliv-
ered in the US with a greater focus on acute illness rather
than chronic disease management. Within the constraints
of outpatient clinical encounters, it is challenging for pro-
viders to find time to teach patients self-management
skills. Additionally, providers also may have very limited
resources for patient education such as pamphlets on
gout, ready access to reputable online patient-oriented
education, and support staff for teaching and reinforcing
concepts with patients. Furthermore, most providers have
had little or no training in motivational interviewing or
patient self-management training. We found that know-
ledge and medical beliefs were not higher in patients with
greater health care utilization or chronicity (defined as re-
ceipt of a urate-lowering medication). This suggests that
just recommending more visits with a provider will not
necessarily result in better care. Additionally primary care
providers may need more training in the pharmacologic
and nonpharmacologic management of gout. Innovative
approaches to improve care will need to engage both the
provider and the patient.
Our study is similar to others in the United Kingdom
identifying identify patient beliefs and knowledge deficits
Table 3 Patient knowledge of foods and alcoholic beverages and their risk of causing a gout flare
% agreement that item could cause a gout flare
Food Total population Active gout Not active gout P value
Published evidence of an association between gout episode and level of consumption* (% agreement that item could cause a
gout flare)
Shellfish 55 21 22 0.855
Beer 43 28 45 0.026
Hard liquor (whiskey, gin and vodka) 34 28 34 0.419
Seafood excluding shellfish 23 53 52 0.957
Beef 22 11 24 0.046
Pork 7 4 8 0.288
No associations seen (% agreement that item could cause a gout flare)
Vegetables 58 47 59 0.131
Chicken 55 42 57 0.051
Legumes (beans and lentils) 39 32 39 0.356
Wine 13 4 15 0.030
Overall score (mean± SD) 3.4 (2.3) 2.7 (2.2) 3.6 (2.2) 0.014
*Epidemiologic studies have identified a relationship between the dietary intake and gout flares.
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regarding dietary factors and medication usage in the
management of gout [10,28]. However, the results pre-
sented here should be interpreted within the context of
some limitations. The study is limited by the fact that
this was based in a small managed care plan. However,
we believe the sample represents a typical clinical prac-
tice with very few patients cared for by a rheumatologist
and approximately half of the patients prescribed a
urate-lowering drug. There was limited racial diversity in
our population. In addition, we did not directly assess
the conversations between provider and patients—only
what the patient reported. Accordingly, we do not know
the degree to which patient education was actually pro-
vided. Of note we did not assess health literacy which
may have played a role with patients not being able to
understand the instructions from the provider treating
their gout [29].
Conclusion
In this sample of gout patients cared mostly by primary
care providers, there was limited knowledge regarding
dietary triggers for gout suggesting better education is
needed. There was also lack of awareness regarding the
risk of gout flare with initiation of a urate-lowering
medication. This suggests changes in current clinical
practice should be considered. These include providing
information regarding the short-term and long-term
effects of urate-lowering medications and education on
the impact of dietary factors on triggering an attack.
These educational approaches should be presented in
multiple modes (e.g., orally and in print) as well at mul-
tiple time points. Additionally these messages need to be
reinforced in follow-up encounters or telephone calls.
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